BMC Neuroscience · 2023 · 19 citations · 15 references
MedicineEndocrinologyPharmacologyNeuroendocrinologyReproductive EndocrinologyReproductive PhysiologyGynecologic EndocrinologyHormonal InfluencesMammalian EndocrinologyOvarian PhysiologyPolycystic Ovary SyndromeRodent EndocrinologyApoptotic BiomarkersExperimental Model TestingGamma-aminobutyric Acid ModulatorsHypothalamic InflammationHypothalamic-pituitary-ovarian Axis DysfunctionPolycystic Ovary Syndrome PharmacotherapyPolycystic Ovary Syndrome TreatmentPolycystic Ovary Syndrome-associated Insulin Resistance
Polycystic ovarian syndrome (PCOS) is a known endocrine disorder that has affected many women of childbearing age, and is accompanied by various neurodegenerative conditions. Hence, this study investigates the impact of butyrate in reversing hypothalamic-related disorder, possibly through γ aminobutyric acid (GABA) in a rat model of PCOS. Eight-week-old female Wistar rats were allotted into four groups (n = 5), which include control, butyrate, letrozole, and letrozole + butyrate groups. PCOS was induced by administering 1 mg/kg of letrozole (oral gavage) for 21 days. After confirmation of PCOS, 200 mg/kg of butyrate (oral gavage) was administered for 6 weeks. Rats with PCOS were characterized by elevated levels of plasma insulin and testosterone. Increases in plasma and hypothalamic triglyceride levels, inflammatory biomarker (SDF-1), apoptotic marker (caspase-6), and decreased plasma GnRH were observed. Additionally, a decrease in hypothalamic GABA was revealed. Nevertheless, the administration of butyrate attenuated these alterations. The present study suggests that butyrate ameliorates hypothalamic inflammation in an experimental model of PCOS, a beneficial effect that is accompanied by enhanced GABA production.
15
Evidence for Distinctive and Intrinsic Defects in Insulin Action in Polycystic Ovary Syndrome
Andrea Dunaif, Karen R. Segal, Donna Shelley et al. · Diabetes · 1992 · 517 citations
Medicine, Endocrinology, Gynecology +13